1 **Association of mRNA COVID-19 vaccination with overall survival in patients receiving**
2 **immune checkpoint inhibitors: a retrospective cohort analysis.**
3

4 Mark TK Cheng[1], Jodi L Keen[2], Steven Frost[2], David M Favara[3,4,5]*
5
[1] Department of Haematology, Cambridge University Hospitals NHS Foundation Trust,
Cambridge, UK.
[2] Department of Information Management, Cambridge University Hospitals NHS Foundation
Trust, Cambridge, UK.
[3] Department of Oncology, University of Cambridge, Cambridge, UK.
[4] Department of Oncology, Cambridge University Hospitals NHS Foundation Trust,
Cambridge, UK.
[5] Department of Structural Studies, MRC Laboratory of Molecular Biology, Cambridge, UK.
14
15 *Corresponding author: David M. Favara (dfavara@mrc-lmb.cam.ac.uk or df411@cam.ac.uk)

16
17
18 **Abstract:**
19

Background
A recent retrospective clinical study reported that COVID-19 mRNA vaccination administered
around initiation of immune checkpoint inhibitor (ICI) therapy may be associated with improved
overall survival (OS) in metastatic melanoma and non-small cell lung cancer (NSCLC).
Whether this association is limited to vaccination during ICI initiation or extends across a
broader ICI treatment period remains unclear.
26
Methods
We conducted a single-centre retrospective cohort analysis of patients treated with palliative-
intent ICI therapy at a UK tertiary cancer centre between October 2014 and December 2025.
Demographics, COVID-19 vaccination status, timing, vaccine platform, ICI therapy and tumour
type were extracted from electronic health records. Two COVID-19 vaccination exposure
definitions were assessed: an initial exposure window (vaccination within 100 days of first ICI
cycle) and an extended exposure window (vaccination between 100 days before the first ICI
cycle and 100 days after the final ICI cycle). OS was assessed using Kaplan-Meier methods
and Cox proportional hazards models, with hazard ratios estimated relative to unvaccinated
patients.
37

Results

Among 2109 patients treated with palliative-intent ICI therapy, 515 (24.4%) received at least one COVID-19 vaccine dose. Using the initial exposure window, COVID-19 mRNA vaccination was not associated with a significant difference in OS in the overall cohort or within tumour-specific subgroups. In contrast, under the extended exposure window, mRNA COVID-19 vaccination was associated with longer OS in the all-tumours cohort (HR 0.58; 95% CI 0.46-0.75; p<0.0001), including melanoma (HR 0.35; 95% CI 0.18-0.69; p=0.002) and kidney cancer (HR 0.47; 95% CI 0.28-0.79; p=0.004), but not in NSCLC. In an era-restricted analysis limited to patients receiving ICI therapy from 2020 onwards, the association in the all-tumours cohort persisted (HR 0.76; 95% CI 0.59-0.98; p=0.04) with no statistically significant associations within tumour-specific subgroups.

Conclusions

COVID-19 mRNA vaccination was associated with longer OS only when vaccination exposure was defined across an extended ICI treatment period and not when restricted to vaccination near ICI initiation. Prospective studies are required to determine whether mRNA COVID-19 vaccination during ICI therapy confers a true biological benefit and to define tumour-specific effects.

Introduction:

Grippin *et al*. recently reported compelling retrospective data demonstrating that American patients with advanced non-small cell lung cancer (NSCLC) and metastatic melanoma who received COVID-19 mRNA vaccination within 100 days of initiating immune checkpoint inhibitor (ICI) therapy experienced significantly improved overall survival (OS) compared with unvaccinated patients [1]. This association was not observed for influenza or pneumococcal protein vaccination in NSCLC cohorts [1], suggesting a potential mRNA vaccine-specific effect. Supporting preclinical results showed that non-tumour antigen mRNA vaccines can induce a type I interferon-mediated innate immune response, associated with increased tumour PD-L1 expression and enhanced antigen-presenting cell activation, potentially augmenting tumour-specific T cell responses and sensitivity to ICI therapy [1].

Given the potential clinical implications of these findings, independent validation in different real-world populations is warranted. In particular, it remains unclear whether the reported survival benefit is confined to vaccination administered at or around the time of ICI initiation, or whether vaccination occurring across a broader ICI treatment period may also be associated with improved outcomes. We therefore retrospectively evaluated the association between COVID-19 vaccination timing and overall survival (OS) in a single-centre United Kingdom (UK) cohort of patients treated with palliative-intent ICI therapy across multiple tumour types.

Methods:

A retrospective cohort analysis was conducted using the electronic patient record (EPR) system at Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. Ethical approval was granted by Cambridge University Hospitals NHS Foundation Trust (ID7592; PRN13592). The EPR was queried to identify all patients treated with UK-licensed immune checkpoint inhibitor (ICI) therapy (atezolizumab, avelumab, cemiplimab, dostarlimab, durvalumab, ipilimumab, nivolumab, pembrolizumab, relatilimab, and tremelimumab) between 1 October 2014 and 19 December 2025.

Demographic characteristics, cancer diagnosis information, ICI treatment details (indication, treatment intent, line of therapy, start/end dates, number of ICI cycles), survival data (date of death or last follow-up) and COVID-19 vaccination records (vaccination status, vaccine type, and dates of administration) were extracted from the EPR. Patients alive at the time of database extraction were censored on 19 December 2025. Where discrepancies or ambiguities were identified, patient records were manually reviewed to ensure data accuracy.

As tumour stage was not consistently available across EPR records, treatment intent recorded
at the time of ICI initiation was used as a surrogate measure of disease extent. Original ICI
treatment intent labels within the EPR were heterogeneous and were therefore mapped to a
simplified binary classification scheme. ICI treatments labelled as 'adjuvant' or 'neoadjuvant'
were classified as curative-intent, while records labelled as 'non-curative' for advanced
disease were classified as palliative-intent. For intent records labelled as 'disease modification'
or 'curative', individual patient records were manually reviewed to determine whether
treatment was delivered with curative or palliative intent. To minimise baseline disease-stage
imbalances between vaccination exposure groups, all survival analyses were restricted to
patients treated with palliative-intent ICI therapy.

To evaluate the association between COVID-19 vaccination and survival, two vaccination
exposure definitions were examined. The initial exposure window mirrored that of Grippin et
al, classifying patients as vaccinated if they received at least one COVID-19 vaccine dose
within 100 days of the first ICI cycle. The extended exposure window classified patients as
vaccinated if they received at least one COVID-19 vaccine dose between 100 days before the
first ICI cycle (C1) and 100 days after the final ICI cycle. Unvaccinated patients were defined
as those with no recorded COVID-19 vaccination at any time. Patients who received COVID-
19 vaccination exclusively outside the defined ICI treatment window were excluded from
survival analyses.

Summary statistics were calculated for all palliative-intent treated patients, stratified by
vaccine exposure and tumour type. Overall survival (OS) was analysed using the Kaplan-
Meier method (2), with differences between vaccination subgroups assessed using Cox
proportional hazards models (3). The primary outcome was OS defined as the time from the
first ICI cycle to death from any cause.

Hazard ratios (HRs) were estimated relative to the unvaccinated subgroup with follow-up time
truncated at 60 months. Statistical significance was assessed using two-sided p values and
reported as: ****, $p < 0.0001$; ***, $p < 0.001$; **, $p < 0.01$; *, $p < 0.05$; ns, non-significant. All
analyses were performed using R (v4.4.1) within RStudio (v2025.05.0+496). Cox proportional
hazards analyses were conducted using 'survival' (v3.8.3) and Kaplan-Meier survival curves
were plotted using 'survminer' (v0.5.0).

Results:
Between 1 October 2014 and 19 December 2025, 2,557 patients received ICI therapy at
Addenbrooke's Hospital. Of these, 448 (17.5%) received curative-intent therapy and 2,109

(82.5%) received palliative-intent therapy (**Figure 1A**). Given their earlier-stage disease and smaller numbers, curative-intent patients were excluded and all subsequent analyses were restricted to the palliative-intent cohort.

Among the palliative-intent ICI-treated cohort, 515 (24.4%) had received at least one COVID-19 vaccination at any time during follow-up, while 1594 (75.6%) were unvaccinated. Of all COVID-19 vaccine doses administered, 57.4% were mRNA-based (51.5% Pfizer-BioNTech BNT162b2; 5.9% Moderna mRNA-1273), and 42.6% were adenoviral-vector (AdV) vaccines (AstraZeneca ChAdOx1-S).

Initial exposure window:

Using the initial exposure window, defined to mirror that used by *Grippin et al*, 161 (31.3%) patients received at least one COVID-19 vaccine dose within 100 days of the first ICI cycle, while 354 were vaccinated exclusively outside this window. Among vaccinated patients within this window, 84 (52.1%) received mRNA vaccines only, 75 (46.6%) received AdV vaccines only, and 2 (1.2%) had exposure to both mRNA and AdV vaccines (**Supplementary Fig 1**).

Cohort tumour details and baseline patient characteristics stratified by vaccination status are listed in **Supplementary Table 1-3**. Under this exposure definition, mRNA COVID-19 vaccination was not associated with a significant difference in overall survival in the all-tumour cohort or within tumour-specific subgroups (**Supplementary Table 4**)

Extended exposure window:

Using the extended exposure window, 251 (48.7%) were classified as vaccinated within the defined ICI treatment period, while 264 (51.3%) were vaccinated exclusively outside this window (**Figure 1A**). Among those vaccinated within the ICI treatment period, 118 (47.0%) received mRNA vaccines only, 111 (44.2%) received AdV vaccines only, and 22 (8.8%) had exposure to both mRNA and AdV vaccines.

Within the extended exposure window cohort, tumour types included kidney cancer (n=469; 22.2%), melanoma (n=465; 22.0%), lung cancer (non-small cell lung cancer [NSCLC]; n=313; 14.8%) and a heterogeneous group of remaining tumour types (n=862; 40.8%) (**Supplementary Table 5-6**).

Baseline characteristics stratified by COVID-19 vaccination status and tumour type are shown in **Supplementary Table 7**. Vaccination subgroups were broadly comparable with respect to sex, age at diagnosis, Eastern Cooperative Oncology Group (ECOG) performance status,

body mass index and ethnicity. Within tumour-specific subgroups, baseline characteristics were generally similar across vaccination groups. The melanoma subgroup was well balanced, while the kidney cancer and lung cancer (NSCLC) subgroups showed modest variability in sex distribution, likely attributable to small vaccinated sample sizes. In the heterogeneous remaining tumour types subgroup, a higher proportion of female patients was observed among vaccinated individuals, while other baseline characteristics remained comparable.

Using this exposure definition, receipt of mRNA-based COVID-19 vaccination during the ICI treatment period was associated with significantly improved overall survival (OS) compared with unvaccinated patients in the all-tumours cohort (HR 0.58; 95% CI 0.46-0.75; p<0.0001; **Figure 1B**), kidney cancer (HR 0.47; 95% CI 0.28-0.79; p=0.004; **Figure 1C**), melanoma (HR 0.35; 95% CI 0.18-0.69; p = 0.002; **Figure 1D**), and remaining tumour types cohort (HR 0.65; 95% CI 0.45-0.94; p=0.02; **Figure 1F**). No significant OS difference was observed in patients with lung cancer (NSCLC) (HR 1.25, 95% CI 0.72-2.15; p=0.4; **Figure 1E**).

Median OS among mRNA-vaccinated patients was 32.99 compared with 15.77 months in unvaccinated patients in the all-tumours cohort. Corresponding median OS values were 59.96 vs 20.73 months in kidney cancer, not reached vs 15.47 months in melanoma, and 28.45 vs 14.32 months in the remaining tumour types group (**Supplementary Table 8**). Estimated OS at 60 months was higher in mRNA-vaccinated patients compared with unvaccinated patients in the all-tumours, kidney cancer, melanoma and remaining tumour types cohorts (**Supplementary Table 8**).

AdV vaccination within the ICI treatment period was associated with improved OS in the all-tumours cohort (HR 0.71; 95% CI 0.56-0.90; p=0.004; **Figure 1B**) and in melanoma (HR 0.56; 95% CI 0.32-0.96; p=0.04; **Figure 1D**), but not in kidney cancer, lung cancer (NSCLC) or remaining tumour types (**Figure 1B-F**; **Supplementary Table 8**). Median OS among AdV-vaccinated patients was 24.74 months in the all-tumour cohort and 39.2 months in melanoma, with corresponding 60-month OS estimates of 31.5% and 44.0%, respectively.

To address potential confounding related to treatment era, we performed an era-restricted analysis limited to patients initiating ICI therapy from 1 January 2020 onwards. In this restricted cohort, mRNA COVID-19 vaccination within the extended exposure window was associated with a longer OS in the all-tumours cohort (HR 0.76; 95% CI 0.59-0.98; p=0.04). No statistically significant associations were observed within tumour-specific subgroups for either vaccine platform (**Supplementary Table 9**).

Discussion:

In this single-centre UK retrospective cohort of patients treated with palliative-intent immune checkpoint inhibitor (ICI) therapy, we were unable to replicate the survival benefit associated with COVID-19 mRNA when exposure was restricted to the initial ICI exposure window, as defined in prior work (1). In contrast, when vaccination exposure was defined using an extended ICI treatment window, mRNA COVID-19 vaccination was associated with a statistically significant longer overall survival in the all-tumours cohort and in several tumour-specific subgroups (melanoma, kidney cancer and a heterogeneous combined group of remaining tumour types). This divergence raises questions regarding retrospective time-dependent bias and survival selection.

The association observed in melanoma under the extended exposure definition is consistent with retrospective findings by Grippin *et al* who demonstrated improved overall survival among patients with metastatic melanoma receiving COVID-19 vaccination within 100 days of ICI initiation (1). Preclinical data from that study suggested that innate immune activation driven by the mRNA lipid nanoparticle (LNP) platform, rather than antigen specificity, may enhance sensitivity to immune checkpoint blockade (1). Whereas Grippin *et al*. reported a balanced distribution of Pfizer-BioNTech and Moderna mRNA vaccines (LSCNC: 65% vs 35%; melanoma: 48.8% vs 51.2%), (1) Moderna exposure in our all-patient cohort was uncommon (5.9%), with Pfizer-BioNTech predominating (51.5%) and the remainder (42.6%) receiving the adenoviral-vector AstraZeneca vaccine. Although Pfizer-BioNTech and Moderna mRNA vaccines differ in mRNA dose per administration (30 μg prime/30 μg boost (4) vs 100 μg prime/50 μg boost (5), respectively), evaluation of survival by mRNA vaccine subtype was not feasible in our cohort due to limited Moderna exposure and was not undertaken in the study by Grippin *et al*. In contrast, we did not observe a similar association in non-small cell lung cancer, consistent with findings from an independent retrospective cohort reported as a preprint (6). Our analysis identified an association with kidney cancer under the extended exposure window, a tumour type not previously reported in this context.

A small but growing number of case reports have described solid and haematological tumour regression or remission following COVID-19 mRNA vaccination, occurring both in patients receiving ICI therapy and those not on immunotherapy. Reported cases include melanoma (7), kidney cancer (8), cholangiocarcinoma (8), parotid and salivary tumours (9, 10) and lymphoma (10). While anecdotal, these observations, together with the translational findings reported by Grippin *et al*, emphasise the need for prospective clinical studies to define causality, optimal timing and tumour specificity.

Although Adenoviral-vector COVID-19 vaccines were not investigated in the study by Grippin *et al.* we observed an association between adenoviral-vector vaccination and improved overall survival in the all-tumours cohort and in melanoma when using the extended exposure definition. Given the retrospective design and limited subgroup sizes, this finding should be interpreted cautiously and considered hypothesis generating.

To address potential confounding relating to treatment era, we performed an era-restricted analysis limited to patients receiving ICI therapy from 1 January 2020 onwards. Under this restriction, the association between mRNA vaccination and overall survival in the all-tumour cohort persisted but was attenuated, with no statistically significant associations observed within tumour-specific subgroups.

Our study has multiple limitations. The retrospective observational design precludes causal inference and is vulnerable to confounding, including immortal time bias and survivor bias, particularly when vaccination exposure is allowed to occur across extended treatment periods. Vaccinated subgroup sizes were small for some tumour types, particularly NSCLC, limiting statistical power and precluding multivariable adjustment. Tumour stage was approximated using treatment intent, and outcomes may have been influenced by changes in clinical practice over the 11-year study period (evolving indications for ICI therapy, earlier lines of therapy and improvements in supportive care). Concerns regarding time-related bias in retrospective vaccine-ICI studies have been highlighted in a pre-print which re-analysed the Grippin *et al.* dataset using target trial emulation and found no evidence of improved overall survival or progression-free survival in advanced NSCLC and melanoma after accounting for immortal time bias (11).

In summary, COVID-19 mRNA vaccination was associated with longer overall survival only when vaccination exposure was defined across an extended ICI treatment period, with consistent findings in melanoma and kidney cancer, but not in NSCLC. These results are hypothesis generating and should be interpreted cautiously. Prospective clinical studies are required to determine whether COVID-19 mRNA vaccination at specific time points during ICI therapy provides a true biological benefit and to define tumour-specific effects.

Acknowledgements:
The authors thank Dr Keren Turton and Dr Nicola Thompson for their constructive comments.

Contributions:

D.M.F designed the study. J.L.K and D.M.F extracted clinical data. D.M.F and M.T.K.C

performed data and statistical analyses. D.M.F wrote the manuscript with all authors

contributing to editing.

Competing interests:

The authors declare no competing interests.

Ethics approval:

Ethical approval was granted by Cambridge University Hospitals NHS Foundation Trust

(ID7592; PRN13592).

Data availability statement:

All data relevant to the study are included in the article or uploaded as supplementary

information

Open access

For the purpose of open access, the MRC Laboratory of Molecular Biology has applied a CC

BY public copyright licence to any Author Accepted Manuscript version arising.

References:

1.　　Grippin AJ, Marconi C, Copling S, Li N, Braun C, Woody C, et al. SARS-CoV-2

mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature.

2025;647(8089):488-97.

2.　　Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations.

Journal of the American Statistical Association. 1958;53(282):457-81.

3.　　Cox DR. Regression Models and Life-Tables. Journal of the Royal Statistical Society:

Series B (Methodological). 1972;34(2):187-202.

4.　　Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety

and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. The New England journal of

medicine. 2020;383(27):2603-15.

5.　　Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and

Safety of the mRNA-1273 SARS-CoV-2 Vaccine. The New England journal of medicine.

2021;384(5):403-16.

6.　　Jee J, Zhang J, Lavery JA, Waters M, Fong C, Minn A, et al. Deconvolving SARS-

CoV-2 mRNA vaccine impact on immunotherapy-related survival in a pandemic. medRxiv.

2025:2025.11.21.25340753.

7.   Bafaloukos D, Petraki K, Bousmpoukea A, Chatzichristou E, Pieris I, Koutserimpas

C, et al. Therapeutic Effect of mRNA SARS-CoV-2 Vaccine on Melanoma Skin Metastases.

Vaccines (Basel). 2022;10(4).

8.   Tan JL. COVID-19 induced remission of biliary and renal cell carcinomas. Journal of

Clinical Oncology. 2023;41(16_suppl):e14598-e.

9.   Sousa LG, McGrail DJ, Li K, Marques-Piubelli ML, Gonzalez C, Dai H, et al.

Spontaneous tumor regression following COVID-19 vaccination. Journal for immunotherapy

of cancer. 2022;10(3).

10.   Meo C, Palma G, Bruzzese F, Budillon A, Napoli C, de Nigris F. Spontaneous cancer

remission after COVID-19: insights from the pandemic and their relevance for cancer

treatment. Journal of translational medicine. 2023;21(1):273.

11.   Dumas E, Gougis P, Gasparollo L, Spano J-P, Stensrud MJ. Avoiding biases when

estimating effects of COVID-19 vaccination during immune checkpoint inhibitor therapy.

medRxiv. 2025:2025.11.03.25339367.

Figure 1. Overall survival among patients with cancer treated with palliative-intent ICI therapy, according to COVID-19 vaccination status using the extended exposure window. **A**). Flow diagram illustrating retrospective cohort selection and subgroup definitions. Patients receiving curative-intent ICI therapy (neoadjuvant or adjuvant treatment) were excluded from survival analyses. Vaccination within the ICI treatment period was defined according to the extended exposure window as receipt of at least one COVID-19 vaccine dose between 100 days before the first ICI cycle (C1) and 100 days after the final ICI cycle (Cx). **B-F.** Kaplan-Meier curves showing overall survival among patients treated with palliative-intent ICI therapy, stratified by

COVID-19 vaccination subgroup (mRNA only, AdV only, or unvaccinated) for all tumours (**B**),

kidney cancer **(C),** melanoma (**D**), lung cancer (NSCLC) (**E**), remaining tumour types (**F**).

Hazard ratios for mRNA and AdV vaccination relative to unvaccinated patients were estimated

using Cox proportional hazards models with follow-up censored at 60 months and are

displayed in each panel. Numbers at risk are shown below each plot. Abbreviations: AdV -

adenoviral-vector; C1 - ICI cycle 1; Cx - final ICI cycle; HR - hazard ratio; ICI - immune

checkpoint inhibitor.

347
348
349

351 **Supplementary Figure 1.** Flow diagram illustrating retrospective cohort selection and
352 subgroup definitions using the initial exposure window. Patients receiving curative-intent ICI
353 therapy (neoadjuvant or adjuvant treatment) were excluded from survival analyses.
354 Vaccination within the ICI treatment period was defined using the initial exposure window as
355 receipt of at least one COVID-19 vaccine dose within 100 days of the first ICI cycle (C1).

356
357

Tumour groups	Total patients treated with palliative-intent ICI, n	COVID-19 vaccinated (any time), n	No COVID-19 vaccination, n	Vaccinated within ICI treatment period, n	mRNA only (within ICI treatment period), n	AdV only (within ICI treatment period), n	Mixed (mRNA + AdV) within ICI treatment period, n	Vaccinated outside ICI treatment period, n
All	2109	515	1594	161	84	75	2	354
KIDNEY	469	139	330	50	22	27	1	89
MELANOMA	465	127	338	27	15	11	1	100
LUNG_NSCLC	313	59	254	20	14	6	0	39
Remaining tumours	862	190	672	64	33	31	0	126

Supplementary Table 1. COVID-19 vaccination status and timing according to the initial exposure window among patients treated with palliative-intent ICI therapy, stratified by major tumour types. Vaccination within the ICI treatment period was defined using the initial exposure window (within 100 days within the first ICI cycle). Abbreviations: AdV - adenovirus vaccine; ICI - immune checkpoint inhibitor.

Tumour groups	Total patients treated with palliative-intent ICI, n	COVID-19 vaccinated (any time), n	No COVID-19 vaccination, n	Vaccinated within ICI treatment period, n	mRNA only (within ICI treatment period), n	AdV only (within ICI treatment period), n	Mixed (mRNA + AdV) within ICI treatment period, n	Vaccinated outside ICI treatment period, n
HEAD_AND_NECK	150	35	115	13	10	3	0	22
GYNAECOLOGICAL	88	32	56	10	7	3	0	22
SKIN_SCC	86	10	76	2	1	1	0	8
HEPATOBILIARY	84	22	62	4	1	3	0	18
MESOTHELIOMA_lung	73	17	56	9	5	4	0	8
LOWER_GI_TRACT	55	21	34	8	3	5	0	13
LUNG_SC	54	9	45	4	0	4	0	5
BLADDER	42	7	35	2	0	2	0	5
OESOPHAGUS	39	8	31	3	1	2	0	5
BREAST	25	4	21	2	2	0	0	2
GASTRIC	21	4	17	0	0	0	0	4
PROSTATE	21	6	15	3	1	2	0	3
UROTHELIAL	21	2	19	1	0	1	0	1
SARCOMA	17	5	12	0	0	0	0	5
MERKEL	16	1	15	0	0	0	0	1
PANCREAS	16	1	15	0	0	0	0	1
CERVIX	13	1	12	0	0	0	0	1
HAEM	6	0	6	0	0	0	0	0
SKIN_BCC	6	1	5	0	0	0	0	1
LUNG_LC	5	2	3	1	0	1	0	1
NEUROENDOCRINE	5	0	5	0	0	0	0	0
PRIMARY_BRAIN	4	1	3	1	1	0	0	0
CUP	3	0	3	0	0	0	0	0
GALLBLADDER	3	1	2	1	1	0	0	0
ADRENAL	2	0	2	0	0	0	0	0
MESOTHELIOMA_peritoneal	2	0	2	0	0	0	0	0

THYMIC	2	0	2	0	0	0	0	0
NUT_CARCINOMA	1	0	1	0	0	0	0	0
SKIN_ECCRINE_ADENOCARCINOMA	1	0	1	0	0	0	0	0
THYROID	1	0	1	0	0	0	0	0
TOTAL	**862**	**190**	**672**	**64**	**33**	**31**	**0**	**126**

Supplementary Table 2. COVID-19 vaccination status and timing according to the initial exposure window among patients treated with palliative-intent ICI therapy, for tumour types comprising the "Remaining tumour types" category. Abbreviations: AdV - adenovirus vaccine; ICI - immune checkpoint inhibitor.

	Baseline characteristics	mRNA only	AdV only	Unvaccinated
All tumours	Total n	84	75	1594
	Treatment intent: curative, n (%)	0 (0%)	0 (0%)	0 (0%)
	Treatment intent: palliative, n (%)	84 (100%)	75 (100%)	1594 (100%)
	Female n (%)	35 (41.7%)	35 (46.7%)	607 (38.1%)
	Median age at diagnosis (IQR)	68 (60-74)	67 (58-72)	68 (59-75)
	Mean ECOG performance status (SD)	0.49 (0.72)	0.45 (0.6)	0.54 (0.6)
	Mean BMI (SD)	25.99 (5.57)	25.73 (5.84)	26.15 (5.7)
	Ethnicity: white British, n (%)	72 (85.7%)	66 (88%)	1396 (87.6%)
	Mean total ICI cycles received (SD)	10.69 (13.22)	10.31 (11.76)	7.84 (9.23)
Kidney cancer	Total n	15	11	338
	Treatment intent: curative, n (%)	0 (0%)	0 (0%)	0 (0%)
	Treatment intent: palliative, n (%)	15 (100%)	11 (100%)	338 (100%)
	Female n (%)	5 (33.3%)	6 (54.5%)	143 (42.3%)
	Median age at diagnosis (IQR)	64 (58-76)	70.5 (53-71.8)	67 (58-74)
	Mean ECOG performance status (SD)	0.29 (0.47)	0.18 (0.4)	0.54 (0.6)
	Mean BMI (SD)	29.02 (5.3)	25.61 (6.23)	27.63 (6.03)
	Ethnicity: white British, n (%)	13 (86.7%)	11 (100%)	295 (87.3%)
	Mean total ICI cycles received (SD)	6.4 (4.94)	6.64 (7.05)	6.17 (7.55)
Melanoma	Total n	22	27	330
	Treatment intent: curative, n (%)	0 (0%)	0 (0%)	0 (0%)
	Treatment intent: palliative, n (%)	22 (100%)	27 (100%)	330 (100%)
	Female n (%)	7 (31.8%)	10 (37%)	100 (30.3%)
	Median age at diagnosis (IQR)	68 (61-73)	64.5 (57.2-71.5)	65 (59-73)
	Mean ECOG performance status (SD)	0.5 (0.6)	0.48 (0.7)	0.42 (0.61)
	Mean BMI (SD)	26.53 (5.21)	26.65 (6.29)	27 (5.92)
	Ethnicity: white British, n (%)	19 (86.4%)	27 (100%)	292 (88.5%)
	Mean total ICI cycles received (SD)	13.41 (14.22)	12.44 (13.39)	8.08 (9.25)
Lung cancer (NSCLC)	Total n	14	6	254
	Treatment intent: curative, n (%)	0 (0%)	0 (0%)	0 (0%)
	Treatment intent: palliative, n (%)	14 (100%)	6 (100%)	254 (100%)
	Female n (%)	7 (50%)	2 (33.3%)	104 (40.9%)
	Median age at diagnosis (IQR)	67 (64.5-68)	66.5 (62-75.5)	69 (61-75)
	Mean ECOG performance status (SD)	1 (0.96)	0.83 (0.41)	0.74 (0.57)
	Mean BMI (SD)	26.16 (4.78)	28.52 (5.16)	24.89 (5.15)
	Ethnicity: white British, n (%)	11 (78.6%)	3 (50%)	223 (87.8%)
	Mean total ICI cycles received (SD)	6.64 (3.27)	10.5 (6.89)	8.9 (8.54)
Remaining tumour types	Total n	33	31	672
	Treatment intent: curative, n (%)	0 (0%)	0 (0%)	0 (0%)
	Treatment intent: palliative, n (%)	33 (100%)	31 (100%)	672 (100%)
	Female n (%)	16 (48.5%)	17 (54.8%)	260 (38.7%)
	Median age at diagnosis (IQR)	70 (61.5-75.2)	67 (61-72.5)	69 (60-76)
	Mean ECOG performance status (SD)	0.36 (0.7)	0.45 (0.57)	0.53 (0.6)
	Mean BMI (SD)	24.18 (5.75)	24.42 (5.32)	25.46 (5.41)
	Ethnicity: white British, n (%)	29 (87.9%)	25 (80.6%)	586 (87.2%)
	Mean total ICI cycles received (SD)	12.55 (16.77)	9.71 (12.32)	8.17 (10.12)

Supplementary Table 3. Baseline characteristics of patients treated with palliative-intent ICI therapy according to COVID-19 vaccination subgroup and tumour type under the initial exposure window. Values are reported as number (percentage), median (IQR) and mean (SD)

375   as indicated. Abbreviations: BMI - body mass index; ECOG - Eastern Cooperative Oncology

376   Group; ICI - immune checkpoint inhibitor; IQR - interquartile range; SD - standard deviation.

	Subgroups	Median OS (months)	OS 24 months	OS 36 months	OS 48 months	OS 60 months	HR vs not vaccinated (censored at 60 months)	95% CI	*p* value
All tumours	not vaccinated	15.77	39.1%	31.4%	25.3%	22.2%			
	mRNA only	23.51	48.8%	38.1%	30.8%	30.8%	0.76	0.58-0.99	0.04
	AdV only	18.92	36.0%	28.0%	24.0%	24.0%	0.93	0.71-1.22	0.6
Kidney cancer	not vaccinated	20.73	46.6%	37.4%	27.7%	24.8%			
	mRNA only	36.80	63.6%	50.0%	40.4%	40.4%	0.62	0.35-1.09	0.1
	AdV only	24.71	51.9%	40.7%	33.3%	33.3%	0.77	0.47-1.25	0.3
Melanoma	not vaccinated	15.47	39.2%	33.5%	30.7%	26.8%			
	mRNA only	44.06	66.7%	60.0%	46.7%	46.7%	0.55	0.27-1.11	0.09
	AdV only	19.19	27.3%	27.3%	27.3%	27.3%	0.96	0.47-1.94	0.9
Lung cancer (NSCLC)	not vaccinated	13.50	32.8%	26.0%	21.9%	18.8%			
	mRNA only	9.46	14.3%	7.1%	7.1%	7.1%	1.49	0.85-2.62	0.2
	AdV only	14.42	16.7%	16.7%	16.7%	16.7%	1.00	0.41-2.43	1
Remaining tumour types	not vaccinated	14.32	37.9%	29.2%	21.3%	18.4%			
	mRNA only	21.45	45.5%	33.3%	27.3%	27.3%	0.77	0.51-1.16	0.2
	AdV only	11.37	29.0%	19.4%	16.1%	16.1%	1.12	0.75-1.66	0.6

Supplementary Table 4. Overall survival (OS) outcomes for COVID-19 vaccination subgroups and tumour types using the initial exposure window. OS outcomes are reported for patients classified according to the initial vaccination exposure window, defined as receipt of at least one COVID-19 vaccine dose within 100 days of the first ICI cycle. Hazard ratios (HRs) were estimated using Cox proportional hazards models and are reported relative to the unvaccinated subgroup with follow-up censored at 60 months. (Abbreviations: AdV - adenovirus vaccine; CI - confidence interval; HR - hazard ratio; OS - overall survival).

Tumour groups	Total patients treated with palliative-intent ICI, n	COVID-19 vaccinated (any time), n	No COVID-19 vaccination, n	Vaccinated within ICI treatment period, n	mRNA only (within ICI treatment period), n	AdV only (within ICI treatment period), n	Mixed (mRNA + AdV) within ICI treatment period, n	Vaccinated outside ICI treatment period, n
All	2109	515	1594	251	118	111	22	264
KIDNEY	469	139	330	73	32	32	9	66
MELANOMA	465	127	338	54	24	25	5	73
LUNG_NSCLC	313	59	254	32	16	16	0	27
Remaining tumour types	862	190	672	92	46	38	8	98

385 **Supplementary Table 5.** COVID-19 vaccination status and timing according to the extended

386 exposure window among patients treated with palliative-intent ICI therapy, stratified by major

387 tumour types. Vaccination within the ICI treatment period was defined using the extended

388 exposure window (100 days before the first ICI cycle to 100 days after the final ICI cycle).

389 Abbreviations: AdV - adenovirus vaccine; ICI - immune checkpoint inhibitor.

Tumours comprising the group 'Remaining tumour types'	Total patients treated with palliative-intent ICI, n	COVID-19 vaccinated (any time), n	No COVID-19 vaccination, n	Vaccinated within ICI treatment period, n	mRNA only (within ICI treatment period), n	AdV only (within ICI treatment period), n	Mixed (mRNA + AdV) within ICI treatment period, n	Vaccinated outside ICI treatment period, n
HEAD_AND_NECK	150	35	115	18	12	6	0	17
GYNAECOLOGICAL	88	32	56	19	10	9	0	13
SKIN_SCC	86	10	76	3	2	1	0	7
HEPATOBILIARY	84	22	62	6	1	3	2	16
MESOTHELIOMA_lung	73	17	56	9	5	4	0	8
LOWER_GI_TRACT	55	21	34	11	5	4	2	10
LUNG_SC	54	9	45	6	2	3	1	3
BLADDER	42	7	35	3	1	1	1	4
OESOPHAGUS	39	8	31	5	1	4	0	3
BREAST	25	4	21	2	2	0	0	2
GASTRIC	21	2	19	2	1	1	0	0
PROSTATE	21	6	15	5	2	1	2	1
UROTHELIAL	21	4	17	0	0	0	0	4
SARCOMA	17	5	12	0	0	0	0	5
MERKEL	16	1	15	0	0	0	0	1
PANCREAS	16	1	15	0	0	0	0	1
CERVIX	13	1	12	0	0	0	0	1
HAEM	6	1	5	0	0	0	0	1
SKIN_BCC	6	0	6	0	0	0	0	0
LUNG_LC	5	0	5	0	0	0	0	0
NEUROENDOCRINE	5	2	3	1	0	1	0	1
PRIMARY_BRAIN	4	1	3	1	1	0	0	0
CUP	3	1	2	1	1	0	0	0
GALLBLADDER	3	0	3	0	0	0	0	0
ADRENAL	2	0	2	0	0	0	0	0
MESOTHELIOMA_peritoneal	2	0	2	0	0	0	0	0
THYMIC	2	0	2	0	0	0	0	0
NUT_CARCINOMA	1	0	1	0	0	0	0	0
SKIN_ECCRINE_ADENOCARCINOMA	1	0	1	0	0	0	0	0
THYROID	1	0	1	0	0	0	0	0
TOTAL	862	190	672	92	46	38	8	98

409 **Supplementary Table 6.** COVID-19 vaccination status and timing according to the extended

410 exposure window among patients treated with palliative-intent ICI therapy, for tumour types

411 comprising the "Remaining tumour types" category. Abbreviations: AdV - adenovirus

412 vaccine; ICI - immune checkpoint inhibitor.

	Baseline characteristics	mRNA only	AdV only	Unvaccinated
All tumours	Total n	118	111	1594
	Treatment intent: curative, n (%)	0 (0%)	0 (0%)	0 (0%)
	Treatment intent: palliative, n (%)	118 (100%)	111 (100%)	1594 (100%)
	Female n (%)	47 (39.8%)	53 (47.7%)	607 (38.1%)
	Median age at diagnosis (IQR)	68 (60-75)	67 (57.5-72)	68 (59-75)
	Mean ECOG performance status (SD)	0.53 (0.7)	0.49 (0.64)	0.54 (0.6)
	Mean BMI (SD)	26.3 (5.48)	25.77 (5.31)	26.15 (5.7)
	Ethnicity: white British, n (%)	103 (87.3%)	98 (88.3%)	1396 (87.6%)
	Mean total ICI cycles received (SD)	14.49 (16.26)	12.47 (11.79)	7.84 (9.23)
Kidney cancer	Total n	32	32	330
	Treatment intent: curative, n (%)	0 (0%)	0 (0%)	0 (0%)
	Treatment intent: palliative, n (%)	32 (100%)	32 (100%)	330 (100%)
	Female n (%)	8 (25%)	14 (43.8%)	100 (30.3%)
	Median age at diagnosis (IQR)	68 (61-74)	64.5 (54.8-69.8)	65 (59-73)
	Mean ECOG performance status (SD)	0.56 (0.56)	0.59 (0.71)	0.42 (0.61)
	Mean BMI (SD)	27.18 (5.86)	25.97 (5.36)	27 (5.92)
	Ethnicity: white British, n (%)	28 (87.5%)	31 (96.9%)	292 (88.5%)
	Mean total ICI cycles received (SD)	16.44 (14.57)	11.25 (12.53)	8.08 (9.25)
Melanoma	Total n	24	25	338
	Treatment intent: curative, n (%)	0 (0%)	0 (0%)	0 (0%)
	Treatment intent: palliative, n (%)	24 (100%)	25 (100%)	338 (100%)
	Female n (%)	10 (41.7%)	11 (44%)	143 (42.3%)
	Median age at diagnosis (IQR)	60.5 (53-70.8)	70.5 (59-72.8)	67 (58-74)
	Mean ECOG performance status (SD)	0.3 (0.47)	0.28 (0.46)	0.54 (0.6)
	Mean BMI (SD)	28.15 (5.07)	26.48 (5.18)	27.63 (6.03)
	Ethnicity: white British, n (%)	21 (87.5%)	24 (96%)	295 (87.3%)
	Mean total ICI cycles received (SD)	13.46 (14.36)	13.88 (12.29)	6.17 (7.55)
Lung cancer (NSCLC)	Total n	16	16	254
	Treatment intent: curative, n (%)	0 (0%)	0 (0%)	0 (0%)
	Treatment intent: palliative, n (%)	16 (100%)	16 (100%)	254 (100%)
	Female n (%)	8 (50%)	5 (31.2%)	104 (40.9%)
	Median age at diagnosis (IQR)	67 (65.5-68)	68.5 (61.8-70.2)	69 (61-75)
	Mean ECOG performance status (SD)	1 (0.89)	0.75 (0.77)	0.74 (0.57)
	Mean BMI (SD)	25.81 (4.55)	25.73 (4.97)	24.89 (5.15)
	Ethnicity: white British, n (%)	13 (81.2%)	12 (75%)	223 (87.8%)
	Mean total ICI cycles received (SD)	7.19 (4.25)	15.31 (8.1)	8.9 (8.54)
Remaining tumour types	Total n	46	38	672
	Treatment intent: curative, n (%)	0 (0%)	0 (0%)	0 (0%)
	Treatment intent: palliative, n (%)	46 (100%)	38 (100%)	672 (100%)
	Female n (%)	21 (45.7%)	23 (60.5%)	260 (38.7%)
	Median age at diagnosis (IQR)	71 (62-76)	66 (57-72)	69 (60-76)
	Mean ECOG performance status (SD)	0.46 (0.75)	0.42 (0.6)	0.53 (0.6)
	Mean BMI (SD)	24.89 (5.47)	25.15 (5.61)	25.46 (5.41)
	Ethnicity: white British, n (%)	41 (89.1%)	31 (81.6%)	586 (87.2%)
	Mean total ICI cycles received (SD)	16.22 (20.12)	11.37 (12.24)	8.17 (10.12)

414 **Supplementary Table 7.** Baseline characteristics of patients treated with palliative-intent ICI

415 therapy according to COVID-19 vaccination subgroup and tumour type, using the extended

416 exposure window. Values are reported as number (percentage), median (IQR) and mean (SD)

417   as indicated. Abbreviations: BMI - body mass index; ECOG - Eastern Cooperative Oncology
418   Group; ICI - immune checkpoint inhibitor; IQR - interquartile range; SD - standard deviation.

	Subgroups	Median OS (months)	OS 24 months	OS 36 months	OS 48 months	OS 60 months	HR vs not vaccinated (censored at 60 months)	95% CI	p value
All tumours	not vaccinated	15.77	39.1%	31.4%	25.3%	22.2%			
	mRNA only	32.99	58.5%	48.2%	42.1%	39.1%	0.58	0.46-0.75	0.00002 ****
	AdV only	24.74	51.4%	39.6%	33.3%	31.5%	0.71	0.56-0.90	0.004 **
Kidney cancer	not vaccinated	20.73	46.6%	37.4%	27.7%	24.8%			
	mRNA only	59.96	71.9%	62.5%	55.9%	44.5%	0.47	0.28-0.79	0.004 **
	AdV only	24.72	53.1%	37.5%	28.1%	28.1%	0.85	0.55-1.31	0.5
Melanoma	not vaccinated	15.47	39.2%	33.5%	30.7%	26.8%			
	mRNA only	Not reached	75.0%	70.8%	62.5%	62.5%	0.35	0.18-0.69	0.002 **
	AdV only	39.20	60.0%	52.0%	48.0%	44.0%	0.56	0.32-0.96	0.04 *
Lung cancer (NSCLC)	not vaccinated	13.50	32.8%	26.0%	21.9%	18.8%			
	mRNA only	10.23	25.0%	9.4%	9.4%	9.4%	1.25	0.72-2.15	0.4
	AdV only	25.63	50.0%	31.3%	31.3%	31.3%	0.59	0.32-1.09	0.09
Remaining tumour types	not vaccinated	14.32	37.9%	29.2%	21.3%	18.4%			
	mRNA only	28.45	52.2%	39.1%	32.6%	32.6%	0.65	0.45-0.94	0.02 *
	AdV only	17.59	44.7%	36.8%	29.0%	26.3%	0.79	0.53-1.16	0.2

Supplementary Table 8. Overall survival (OS) outcomes for COVID-19 vaccination subgroups and tumour types using the extended exposure window. OS outcomes are reported for patients classified according to the extended vaccination exposure window, defined as receipt of at least one COVID-19 vaccine dose between 100 days before the first ICI cycle and 100 days after the final ICI cycle. Hazard ratios (HRs) were estimated using Cox proportional hazards models and are reported relative to the unvaccinated subgroup with follow-up censored at 60 months. Statistical significance is reported as *$p < 0.05$; **$p < 0.01$; ***$p < 0.001$; ****$p < 0.0001$. (Abbreviations: AdV - adenovirus vaccine; CI - confidence interval; HR - hazard ratio; OS - overall survival).

	Subgroups	Total n at risk	Median OS (months)	OS 24 months	OS 36 months	OS 48 months	OS 60 months	HR vs not vaccinated (censored at 60 months)	95% CI	p value
All tumours	not vaccinated	1144	19.94	44.5%	36.3%	29.2%	28.2%			
	mRNA only	107	29.57	54.2%	43.8%	37.0%	35.9%	0.76	0.59-0.98	0.04 *
	AdV only	95	20.67	43.2%	33.7%	29.5%	28.4%	0.94	0.73-1.21	0.6
Kidney cancer	not vaccinated	228	32.07	58.1%	48.4%	46.2%	46.2%			
	mRNA only	28	46.65	67.9%	57.1%	49.5%	44.5%	0.78	0.45-1.37	0.4
	AdV only	31	24.71	51.6%	38.7%	29.0%	29.0%	1.22	0.76-1.96	0.4
Melanoma	not vaccinated	167	26.71	52.0%	46.8%	43.2%	43.2%			
	mRNA only	20	Not reached	70.0%	65.0%	55.0%	55.0%	0.65	0.32-1.32	0.2
	AdV only	18	20.88	44.4%	38.9%	38.9%	33.3%	1.09	0.58-2.02	0.8
Lung cancer (NSCLC)	not vaccinated	170	13.77	35.8%	26.5%	19.2%	19.2%			
	mRNA only	15	9.59	20.0%	13.3%	13.3%	13.3%	1.40	0.79-2.49	0.3
	AdV only	12	19.14	33.3%	25.0%	25.0%	25.0%	0.77	0.39-1.52	0.4
Remaining tumour types	not vaccinated	579	16.66	39.6%	31.4%	23.1%	21.8%			
	mRNA only	44	24.82	50.0%	36.4%	29.6%	29.6%	0.76	0.52-1.10	0.1
	AdV only	34	13.70	38.2%	29.4%	26.5%	26.5%	0.94	0.62-1.42	0.8

Supplementary Table 9. Overall survival (OS) outcomes for COVID-19 vaccination subgroups and tumour types using the extended

exposure window, restricted to patients receiving ICI therapy from 1 January 2020 onwards. OS outcomes are reported for patients

classified according to the extended vaccination exposure window, defined as receipt of at least one COVID-19 vaccine dose between 100

days before the first ICI cycle and 100 days after the final ICI cycle. Hazard ratios (HRs) were estimated using Cox proportional hazards models

and are reported relative to the unvaccinated subgroup with follow-up censored at 60 months. Statistical significance is reported as *$p < 0.05$;

(Abbreviations: AdV - adenovirus vaccine; CI - confidence interval; HR - hazard ratio; OS - overall survival)